The use of Minilabs® to improve the testing capacity of regulatory authorities in resource limited settings: Tanzanian experience
Abstract The Tanzania Food and Drugs Authority piloted the use of Minilab® kits, a thin-layer-chromatographic based drug quality testing technique, in a two-tier quality assurance program. The program is intended to improve testing capacity with timely screening of the quality of medicines as they e...
Gespeichert in:
Veröffentlicht in: | Health policy (Amsterdam) 2008-08, Vol.87 (2), p.217-222 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 222 |
---|---|
container_issue | 2 |
container_start_page | 217 |
container_title | Health policy (Amsterdam) |
container_volume | 87 |
creator | Risha, Peter Gasper Msuya, Zera Clark, Malcolm Johnson, Keith Ndomondo-Sigonda, Margareth Layloff, Thomas |
description | Abstract The Tanzania Food and Drugs Authority piloted the use of Minilab® kits, a thin-layer-chromatographic based drug quality testing technique, in a two-tier quality assurance program. The program is intended to improve testing capacity with timely screening of the quality of medicines as they enter the market. After 1 week training of inspectors on Minilab® screening techniques, they were stationed at key Ports-of-Entry (POE) to screen the quality of imported medicines. In addition, three non-Ports-of-Entry centres were established to screen samples collected during Post-Marketing-Surveillance. Standard operating procedures (SOPs) were developed to structure and standardize the implementation process. Over 1200 samples were tested using the Minilab® outside the central quality control laboratory (QCL), almost doubling the previous testing capacity. The program contributed to increased regulatory reach and visibility of the Authority throughout the country, serving as a deterrent against entry of substandard medicines into market. The use of Minilab® for quality screening was inexpensive and provided a high sample throughput. However, it suffers from the limitation that it can reliably detect only grossly substandard or wrong drug samples and therefore, it should not be used as an independent testing resource but in conjunction with a full-service quality control laboratory capable of auditing reported substandard results. |
doi_str_mv | 10.1016/j.healthpol.2007.12.010 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69274602</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0168851008000067</els_id><sourcerecordid>69274602</sourcerecordid><originalsourceid>FETCH-LOGICAL-c553t-c2db03c0432bc5de5187e31baaab866ba2dd89438994f91207344c25827f22f73</originalsourceid><addsrcrecordid>eNqNksuO1DAQRSMEYpqBXwCv2HXwI4kdFkij0fDSIBY0a8txKhM3eWE7LcKSD-Ij-DIqdGuQ2AwLuyz53FKV7k2SZ4ymjLLixT5twXSxncYu5ZTKlPGUMnov2TAl-bageXY_2SCptipn9Cx5FMKeIihE8TA5Y4orXgi-SX7sWiBzADI25IMbXGeq8OsniSNx_eTHA5CIQIQQ3XBDrJmMdXFZaQ83c2fi6Bdi5tiO3kUHgbgBf8I4ewukc72LUJMAcZWHl2Rnhu9mcGYg8G0C72Cw8Dh50JguwJNTPU8-v77aXb7dXn988-7y4npr81zEreV1RYWlmeCVzWvIcVMQrDLGVKooKsPrWpWZUGWZNSXjuGuWWZ4rLhvOGynOk-fHvrjX1xk30r0LFrrODDDOQRcll1lB-Z1gLrlQUtwNiqLMSiUEgvIIWj-G4KHRk3e98YtmVK-G6r2-NVSvhmrGNRqKyvdHpYcJ7K0MAFpA1umDFkZJvBY8qFRY3PrEM62VSc05123ssdnT07xz1UP9d4hTHBC4OAKAPhwceB3sH49q58FGXY_uPyZ-9U8P22GwrOm-wAJhj9EY0GbNdECB_rSGdM0oVZhPWkjxGw015qA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>36949833</pqid></control><display><type>article</type><title>The use of Minilabs® to improve the testing capacity of regulatory authorities in resource limited settings: Tanzanian experience</title><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><source>MEDLINE</source><source>RePEc</source><source>Access via ScienceDirect (Elsevier)</source><creator>Risha, Peter Gasper ; Msuya, Zera ; Clark, Malcolm ; Johnson, Keith ; Ndomondo-Sigonda, Margareth ; Layloff, Thomas</creator><creatorcontrib>Risha, Peter Gasper ; Msuya, Zera ; Clark, Malcolm ; Johnson, Keith ; Ndomondo-Sigonda, Margareth ; Layloff, Thomas</creatorcontrib><description>Abstract The Tanzania Food and Drugs Authority piloted the use of Minilab® kits, a thin-layer-chromatographic based drug quality testing technique, in a two-tier quality assurance program. The program is intended to improve testing capacity with timely screening of the quality of medicines as they enter the market. After 1 week training of inspectors on Minilab® screening techniques, they were stationed at key Ports-of-Entry (POE) to screen the quality of imported medicines. In addition, three non-Ports-of-Entry centres were established to screen samples collected during Post-Marketing-Surveillance. Standard operating procedures (SOPs) were developed to structure and standardize the implementation process. Over 1200 samples were tested using the Minilab® outside the central quality control laboratory (QCL), almost doubling the previous testing capacity. The program contributed to increased regulatory reach and visibility of the Authority throughout the country, serving as a deterrent against entry of substandard medicines into market. The use of Minilab® for quality screening was inexpensive and provided a high sample throughput. However, it suffers from the limitation that it can reliably detect only grossly substandard or wrong drug samples and therefore, it should not be used as an independent testing resource but in conjunction with a full-service quality control laboratory capable of auditing reported substandard results.</description><identifier>ISSN: 0168-8510</identifier><identifier>EISSN: 1872-6054</identifier><identifier>DOI: 10.1016/j.healthpol.2007.12.010</identifier><identifier>PMID: 18282632</identifier><language>eng</language><publisher>Ireland: Elsevier Ireland Ltd</publisher><subject>Capacity ; Chromatography, Thin Layer - instrumentation ; Decision Trees ; Drug Contamination - prevention & control ; Drug Industry - standards ; Drug Prescriptions - standards ; Drugs ; Government Regulation ; Health administration ; Health Resources ; Humans ; Imports ; Instillation, Drug ; Internal Medicine ; Internationality ; Minilab ; Monitoring ; Pharmaceuticals ; Product Surveillance, Postmarketing - methods ; Program Evaluation ; Public Health Administration - methods ; Quality assurance ; Quality Control ; Quality standards ; Regulation ; Screening ; Software Design ; Substandard ; Substandard drugs ; Tanzania ; Testing-capacity</subject><ispartof>Health policy (Amsterdam), 2008-08, Vol.87 (2), p.217-222</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2008 Elsevier Ireland Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c553t-c2db03c0432bc5de5187e31baaab866ba2dd89438994f91207344c25827f22f73</citedby><cites>FETCH-LOGICAL-c553t-c2db03c0432bc5de5187e31baaab866ba2dd89438994f91207344c25827f22f73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.healthpol.2007.12.010$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,782,786,3554,4012,27933,27934,31009,46004</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18282632$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://econpapers.repec.org/article/eeehepoli/v_3a87_3ay_3a2008_3ai_3a2_3ap_3a217-222.htm$$DView record in RePEc$$Hfree_for_read</backlink></links><search><creatorcontrib>Risha, Peter Gasper</creatorcontrib><creatorcontrib>Msuya, Zera</creatorcontrib><creatorcontrib>Clark, Malcolm</creatorcontrib><creatorcontrib>Johnson, Keith</creatorcontrib><creatorcontrib>Ndomondo-Sigonda, Margareth</creatorcontrib><creatorcontrib>Layloff, Thomas</creatorcontrib><title>The use of Minilabs® to improve the testing capacity of regulatory authorities in resource limited settings: Tanzanian experience</title><title>Health policy (Amsterdam)</title><addtitle>Health Policy</addtitle><description>Abstract The Tanzania Food and Drugs Authority piloted the use of Minilab® kits, a thin-layer-chromatographic based drug quality testing technique, in a two-tier quality assurance program. The program is intended to improve testing capacity with timely screening of the quality of medicines as they enter the market. After 1 week training of inspectors on Minilab® screening techniques, they were stationed at key Ports-of-Entry (POE) to screen the quality of imported medicines. In addition, three non-Ports-of-Entry centres were established to screen samples collected during Post-Marketing-Surveillance. Standard operating procedures (SOPs) were developed to structure and standardize the implementation process. Over 1200 samples were tested using the Minilab® outside the central quality control laboratory (QCL), almost doubling the previous testing capacity. The program contributed to increased regulatory reach and visibility of the Authority throughout the country, serving as a deterrent against entry of substandard medicines into market. The use of Minilab® for quality screening was inexpensive and provided a high sample throughput. However, it suffers from the limitation that it can reliably detect only grossly substandard or wrong drug samples and therefore, it should not be used as an independent testing resource but in conjunction with a full-service quality control laboratory capable of auditing reported substandard results.</description><subject>Capacity</subject><subject>Chromatography, Thin Layer - instrumentation</subject><subject>Decision Trees</subject><subject>Drug Contamination - prevention & control</subject><subject>Drug Industry - standards</subject><subject>Drug Prescriptions - standards</subject><subject>Drugs</subject><subject>Government Regulation</subject><subject>Health administration</subject><subject>Health Resources</subject><subject>Humans</subject><subject>Imports</subject><subject>Instillation, Drug</subject><subject>Internal Medicine</subject><subject>Internationality</subject><subject>Minilab</subject><subject>Monitoring</subject><subject>Pharmaceuticals</subject><subject>Product Surveillance, Postmarketing - methods</subject><subject>Program Evaluation</subject><subject>Public Health Administration - methods</subject><subject>Quality assurance</subject><subject>Quality Control</subject><subject>Quality standards</subject><subject>Regulation</subject><subject>Screening</subject><subject>Software Design</subject><subject>Substandard</subject><subject>Substandard drugs</subject><subject>Tanzania</subject><subject>Testing-capacity</subject><issn>0168-8510</issn><issn>1872-6054</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>X2L</sourceid><sourceid>7QJ</sourceid><recordid>eNqNksuO1DAQRSMEYpqBXwCv2HXwI4kdFkij0fDSIBY0a8txKhM3eWE7LcKSD-Ij-DIqdGuQ2AwLuyz53FKV7k2SZ4ymjLLixT5twXSxncYu5ZTKlPGUMnov2TAl-bageXY_2SCptipn9Cx5FMKeIihE8TA5Y4orXgi-SX7sWiBzADI25IMbXGeq8OsniSNx_eTHA5CIQIQQ3XBDrJmMdXFZaQ83c2fi6Bdi5tiO3kUHgbgBf8I4ewukc72LUJMAcZWHl2Rnhu9mcGYg8G0C72Cw8Dh50JguwJNTPU8-v77aXb7dXn988-7y4npr81zEreV1RYWlmeCVzWvIcVMQrDLGVKooKsPrWpWZUGWZNSXjuGuWWZ4rLhvOGynOk-fHvrjX1xk30r0LFrrODDDOQRcll1lB-Z1gLrlQUtwNiqLMSiUEgvIIWj-G4KHRk3e98YtmVK-G6r2-NVSvhmrGNRqKyvdHpYcJ7K0MAFpA1umDFkZJvBY8qFRY3PrEM62VSc05123ssdnT07xz1UP9d4hTHBC4OAKAPhwceB3sH49q58FGXY_uPyZ-9U8P22GwrOm-wAJhj9EY0GbNdECB_rSGdM0oVZhPWkjxGw015qA</recordid><startdate>20080801</startdate><enddate>20080801</enddate><creator>Risha, Peter Gasper</creator><creator>Msuya, Zera</creator><creator>Clark, Malcolm</creator><creator>Johnson, Keith</creator><creator>Ndomondo-Sigonda, Margareth</creator><creator>Layloff, Thomas</creator><general>Elsevier Ireland Ltd</general><general>Elsevier</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>DKI</scope><scope>X2L</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8BJ</scope><scope>FQK</scope><scope>JBE</scope><scope>7QJ</scope><scope>7X8</scope></search><sort><creationdate>20080801</creationdate><title>The use of Minilabs® to improve the testing capacity of regulatory authorities in resource limited settings: Tanzanian experience</title><author>Risha, Peter Gasper ; Msuya, Zera ; Clark, Malcolm ; Johnson, Keith ; Ndomondo-Sigonda, Margareth ; Layloff, Thomas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c553t-c2db03c0432bc5de5187e31baaab866ba2dd89438994f91207344c25827f22f73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Capacity</topic><topic>Chromatography, Thin Layer - instrumentation</topic><topic>Decision Trees</topic><topic>Drug Contamination - prevention & control</topic><topic>Drug Industry - standards</topic><topic>Drug Prescriptions - standards</topic><topic>Drugs</topic><topic>Government Regulation</topic><topic>Health administration</topic><topic>Health Resources</topic><topic>Humans</topic><topic>Imports</topic><topic>Instillation, Drug</topic><topic>Internal Medicine</topic><topic>Internationality</topic><topic>Minilab</topic><topic>Monitoring</topic><topic>Pharmaceuticals</topic><topic>Product Surveillance, Postmarketing - methods</topic><topic>Program Evaluation</topic><topic>Public Health Administration - methods</topic><topic>Quality assurance</topic><topic>Quality Control</topic><topic>Quality standards</topic><topic>Regulation</topic><topic>Screening</topic><topic>Software Design</topic><topic>Substandard</topic><topic>Substandard drugs</topic><topic>Tanzania</topic><topic>Testing-capacity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Risha, Peter Gasper</creatorcontrib><creatorcontrib>Msuya, Zera</creatorcontrib><creatorcontrib>Clark, Malcolm</creatorcontrib><creatorcontrib>Johnson, Keith</creatorcontrib><creatorcontrib>Ndomondo-Sigonda, Margareth</creatorcontrib><creatorcontrib>Layloff, Thomas</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>RePEc IDEAS</collection><collection>RePEc</collection><collection>CrossRef</collection><collection>International Bibliography of the Social Sciences (IBSS)</collection><collection>International Bibliography of the Social Sciences</collection><collection>International Bibliography of the Social Sciences</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><collection>MEDLINE - Academic</collection><jtitle>Health policy (Amsterdam)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Risha, Peter Gasper</au><au>Msuya, Zera</au><au>Clark, Malcolm</au><au>Johnson, Keith</au><au>Ndomondo-Sigonda, Margareth</au><au>Layloff, Thomas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The use of Minilabs® to improve the testing capacity of regulatory authorities in resource limited settings: Tanzanian experience</atitle><jtitle>Health policy (Amsterdam)</jtitle><addtitle>Health Policy</addtitle><date>2008-08-01</date><risdate>2008</risdate><volume>87</volume><issue>2</issue><spage>217</spage><epage>222</epage><pages>217-222</pages><issn>0168-8510</issn><eissn>1872-6054</eissn><abstract>Abstract The Tanzania Food and Drugs Authority piloted the use of Minilab® kits, a thin-layer-chromatographic based drug quality testing technique, in a two-tier quality assurance program. The program is intended to improve testing capacity with timely screening of the quality of medicines as they enter the market. After 1 week training of inspectors on Minilab® screening techniques, they were stationed at key Ports-of-Entry (POE) to screen the quality of imported medicines. In addition, three non-Ports-of-Entry centres were established to screen samples collected during Post-Marketing-Surveillance. Standard operating procedures (SOPs) were developed to structure and standardize the implementation process. Over 1200 samples were tested using the Minilab® outside the central quality control laboratory (QCL), almost doubling the previous testing capacity. The program contributed to increased regulatory reach and visibility of the Authority throughout the country, serving as a deterrent against entry of substandard medicines into market. The use of Minilab® for quality screening was inexpensive and provided a high sample throughput. However, it suffers from the limitation that it can reliably detect only grossly substandard or wrong drug samples and therefore, it should not be used as an independent testing resource but in conjunction with a full-service quality control laboratory capable of auditing reported substandard results.</abstract><cop>Ireland</cop><pub>Elsevier Ireland Ltd</pub><pmid>18282632</pmid><doi>10.1016/j.healthpol.2007.12.010</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0168-8510 |
ispartof | Health policy (Amsterdam), 2008-08, Vol.87 (2), p.217-222 |
issn | 0168-8510 1872-6054 |
language | eng |
recordid | cdi_proquest_miscellaneous_69274602 |
source | Applied Social Sciences Index & Abstracts (ASSIA); MEDLINE; RePEc; Access via ScienceDirect (Elsevier) |
subjects | Capacity Chromatography, Thin Layer - instrumentation Decision Trees Drug Contamination - prevention & control Drug Industry - standards Drug Prescriptions - standards Drugs Government Regulation Health administration Health Resources Humans Imports Instillation, Drug Internal Medicine Internationality Minilab Monitoring Pharmaceuticals Product Surveillance, Postmarketing - methods Program Evaluation Public Health Administration - methods Quality assurance Quality Control Quality standards Regulation Screening Software Design Substandard Substandard drugs Tanzania Testing-capacity |
title | The use of Minilabs® to improve the testing capacity of regulatory authorities in resource limited settings: Tanzanian experience |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-11-30T06%3A31%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20use%20of%20Minilabs%C2%AE%20to%20improve%20the%20testing%20capacity%20of%20regulatory%20authorities%20in%20resource%20limited%20settings:%20Tanzanian%20experience&rft.jtitle=Health%20policy%20(Amsterdam)&rft.au=Risha,%20Peter%20Gasper&rft.date=2008-08-01&rft.volume=87&rft.issue=2&rft.spage=217&rft.epage=222&rft.pages=217-222&rft.issn=0168-8510&rft.eissn=1872-6054&rft_id=info:doi/10.1016/j.healthpol.2007.12.010&rft_dat=%3Cproquest_cross%3E69274602%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=36949833&rft_id=info:pmid/18282632&rft_els_id=1_s2_0_S0168851008000067&rfr_iscdi=true |